Palisade Bio, Inc. Common Stock
Here’s whether Palisade Bio, Inc. Common Stock (PALI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 45 — healthy momentum range; strong 1-year return of +155.8%. Concerns: below the 50-day MA (medium-term momentum negative). Currently 39.0% off its 52-week high. Score: +3/7.
PALI is holding above its long-term 200-day MA ($1.73) but has slipped below the 50-day MA ($2.00), pointing to short-term weakness in an otherwise intact trend. An RSI of 45.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +155.8% compares to +24.4% for SPY (beat the market by 131.4%). The current 39.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.